Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.

导出 OA

翻译打印收藏纠错

作者： Charlie W,Lees ^[1] ; J Jasper,Deuring ^[2] ; Michael,Chiorean ^[3] ; Marco,Daperno ^[4] ; Gianluca,Bonfanti ^[5] ; Rebecca,Germino ^[6] ; Pritha Bhadra,Brown ^[6] ; Irene,Modesto ^[6] ; Roger A,Edwards ^[7]

作者单位： Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK. ^[1] Pfizer Netherlands GmbH, Rotterdam, The Netherlands. ^[2] IBD Center of Excellence, Digestive Disease Institute, Virginia Mason, Seattle, WA, USA. ^[3] SC Gastroenterologia, AO Ordine Mauriziano di Torino, Torino, Italy. ^[4] Fair Dynamics Consulting, SRL, Milan, Italy. ^[5] Pfizer Inc, New York, NY, USA. ^[6] Health Services Consulting Corporation, Boxborough, MA, USA. ^[7]

关键词 inflammation outcomes research statistics symptom score or index ulcerative colitis

DOI 10.1177/17562848211054710

PMID 35154388

发布时间 2022-05-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in gastroenterology

2021年14卷

17562848211054710页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.

Therapeutic advances in gastroenterology

相似文献

Therapeutic advances in gastroenterology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies.

Therapeutic advances in gastroenterology

相似文献

Therapeutic advances in gastroenterology

相关期刊

检索历史清除